A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2011
03/17/2011	US20110065146 Expression of HIV polypeptides and production of virus-like particles
03/17/2011	US20110065138 Quantitative Method For Detecting Yessotoxins In Fishery Products On Based On The Activation That The Toxin Produces In Cellular Phosphodiesterases And Therapeutic Use Of This Activation
03/17/2011	US20110065132 Identification of Actinobacillus actinomycetemcomitans Antigens for use in the Diagnosis, Treatment and Monitoring of Periodontal Diseases
03/17/2011	US20110065125 Controlled platelet activation to monitor therapy of adp antagonists
03/17/2011	US20110065109 Rna interference mediating small rna molecules
03/17/2011	US20110064820 Pharmaceutical Compositions Comprising Phosphate-Binding Polymer
03/17/2011	US20110064817 Continuous multi-microencapsulation process for improving the stability and storage life of biologically active ingredients
03/17/2011	US20110064816 Atorvastatin compositions
03/17/2011	US20110064814 Stable pharmaceutical products
03/17/2011	US20110064813 Use of salsalate with or without caffeine and with or without omega 3, and other pharmaceutical compounds in a distinctively unique nano-particulate capsule and tablet
03/17/2011	US20110064812 Oral Solid Dosage Form Containing Nanoparticles and Process of Formulating the Same Using Fish Gelatin
03/17/2011	US20110064811 Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
03/17/2011	US20110064808 Extended release formulation of levetiracetam
03/17/2011	US20110064807 Extended release formulation of levetiracetam
03/17/2011	US20110064806 Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
03/17/2011	US20110064805 Porous cellulose aggregate and molding composition thereof
03/17/2011	US20110064804 Methods and Compositions for the Treatment of CNS-Related Conditions
03/17/2011	US20110064803 Nanoparticulate and controlled release compositions comprising vitamin k2
03/17/2011	US20110064801 Pharmaceutical Formulations Containing an SGLT2 Inhibitor
03/17/2011	US20110064798 Suspension containing hydronium stabilized colloidal silicic acid nanoparticles, formulation obtained from the said dilutesuspension, powder obtained from the said de-hydrated suspension, compositions obtained from the said powder, preparation and use
03/17/2011	US20110064796 Concentrated, inhalable antibiotic formulation
03/17/2011	US20110064792 Method for Opening Tight Junctions
03/17/2011	US20110064791 Self forming, thermodynamically stable liposomes and their applications
03/17/2011	US20110064790 Adaptable modified virus vector to deliver ribosomal ribonucleic acid as a medical treatment device to manage diabetes mellitus and other protein deficient diseases
03/17/2011	US20110064789 Docosahexanoic acid as inhibitor of h. pylori
03/17/2011	US20110064788 Pharmaceutical compositions for treatment of addiction
03/17/2011	US20110064781 Novel heparin entities and methods of use
03/17/2011	US20110064780 Polymeric pheromone formulation and method of use to calm stress-related behavior in mammals over an extended period of time
03/17/2011	US20110064776 Dental composition containing organic nanotube
03/17/2011	US20110064774 Bulking agent
03/17/2011	US20110064773 pharmaceutical compositions comprising a thyroid hormon and their therapeutic use
03/17/2011	US20110064756 Novel sequences of brachyspira, immunogenic compounds, methods for preparation and use thereof
03/17/2011	US20110064755 Methods for producing block copolymer/amphiphilic particles
03/17/2011	US20110064748 Pharmaceutical combination and method for treating tumor
03/17/2011	US20110064742 Somatostatin Receptor Antagonists and Glucose Control or Hypoglycemia
03/17/2011	US20110064739 Medicament, compositions, and substances for treating and identifying adenocarcinoma of the lung
03/17/2011	US20110064735 Methods for treating lymphomas in certain patient populations and screening patients for said therapy
03/17/2011	US20110064730 Method of modulating angiogenesis
03/17/2011	US20110064729 Administration of agents for the treatment of inflammation
03/17/2011	US20110064722 Modulators of alpha-synuclein toxicity
03/17/2011	US20110064721 Cathepsin-d neuroprotection
03/17/2011	US20110064720 Dietary Supplement Compositions and Methods of Making and Using the Same
03/17/2011	US20110064717 Homing endonuclease genes and their targets
03/17/2011	US20110064715 Methods for determining oligosaccharide binding
03/17/2011	US20110064712 Dietary Supplement Compositions and Methods of Making and Using the Same
03/17/2011	US20110064711 Compositions containing coenzyme q-10 and an antioxidant
03/17/2011	US20110064704 Ship-deficiency to increase megakaryocyte and platelet production
03/17/2011	US20110064698 Hepatitis c virus inhibitors
03/17/2011	US20110064697 Hepatitis c virus inhibitors
03/17/2011	US20110064696 Hepatitis c virus inhibitors
03/17/2011	US20110064695 Hepatitis c virus inhibitors
03/17/2011	US20110064694 Anti-hepatitis c activity of meso-tetrakis-porphyrin analogues
03/17/2011	US20110064693 Antiviral Drugs for Treatment of Arenavirus Infection
03/17/2011	US20110064687 Mono-, di- and polyol phosphate esters in personal care formulations
03/17/2011	US20110064683 Personal care compositions with ethylene acrylic acid copolymer aqueous dispersions
03/17/2011	US20110064677 Lipoxin analogs and methods for the treatment of periodontal disease
03/17/2011	US20110064673 New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them
03/17/2011	US20110064671 Modulation of blood brain barrier permeability
03/17/2011	US20110064664 Methods and compositions involving chitosan nanoparticles
03/17/2011	US20110064661 Non-radioactive phospholipid compounds, compositions, and methods of use
03/17/2011	US20110064660 Deuterated alkyl phospholipid compounds, compositions, and methods of use
03/17/2011	US20110064652 Nanoparticles for targeted delivery of active agents to the lung
03/17/2011	US20110062630 Cellulose powder having excellent segregation preventive effect, and compositions thereof
03/17/2011	US20110061651 Formoterol superfine formulation
03/17/2011	US20110061649 Device and method for treating respiratory and other diseases
03/17/2011	DE19626431B4 Verwendung einer pharmazeutische Komposition mit antialkoholischer und nootroper Wirkung Use of a pharmaceutical composition with anti alcoholic and nootropic effect
03/17/2011	DE102010044854A1 Hemmung des Überlebens von Eierstockkrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of ovarian cancer by cyclohexenone from Antrodia camphorata
03/17/2011	DE102010044852A1 Hemmung des Überlebens von Magenkrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of gastric cancer by cyclohexenone from Antrodia camphorata
03/17/2011	DE102010044851A1 Hemmung des Überlebens von Blasenkrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of bladder cancer by cyclohexenone from Antrodia camphorata
03/17/2011	DE102010044850A1 Hemmung des Überlebens von Kolorektalkrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival from colorectal cancer by cyclohexenone from Antrodia camphorata
03/17/2011	CA2811318A1 Concentration and mental performance amplifying formulation
03/17/2011	CA2774144A1 Oncolytic vaccinia virus combination cancer therapy
03/17/2011	CA2774099A1 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof
03/17/2011	CA2773998A1 Substituted carbonyl compound
03/17/2011	CA2773997A1 Aniline compound
03/17/2011	CA2773982A1 Methods for treating irritable bowel syndrome (ibs)
03/17/2011	CA2773957A1 Nutritional compositions for modulating inflammation including exogenous vitamin k2
03/17/2011	CA2773940A1 Nutritional compositions including exogenous vitamin k2
03/17/2011	CA2773854A1 Pharmaceutically useful heterocycle-substituted lactams
03/17/2011	CA2773838A1 N-4(-((3-(2-amino-4pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
03/17/2011	CA2773690A1 Protein matrix vaccines of improved immunogenicity
03/17/2011	CA2773661A1 Ether derivatives of bicyclic heteroaryls
03/17/2011	CA2773628A1 Solid dispersion comprising an anti-hiv agent
03/17/2011	CA2773619A1 Method for the preparation of micro-rna and its therapeutic application
03/17/2011	CA2773615A1 Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
03/17/2011	CA2773614A1 Method of treating cancer by inhibiting trim59 expression or activity
03/17/2011	CA2773611A1 Use of guaifenesin for inhibiting mucin secretion
03/17/2011	CA2773600A1 Use of steroid compounds for inflammatory and autoimmune disorders
03/17/2011	CA2773594A1 Isoxazolidine derivatives
03/17/2011	CA2773591A1 Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
03/17/2011	CA2773590A1 8-oxodihydropurine derivative
03/17/2011	CA2773588A1 Choline fenofibrate delayed release compositions
03/17/2011	CA2773579A1 Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
03/17/2011	CA2773561A1 Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
03/17/2011	CA2773523A1 Compositions and methods for enhancing cognitive and related functions in animals
03/17/2011	CA2773401A1 Composition for improving lactation
03/17/2011	CA2773340A1 Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
03/17/2011	CA2773253A1 Therapeutic agent for chronic pain
03/17/2011	CA2773249A1 Oral suspension formulations of esclicarbazepine acetate
03/17/2011	CA2773218A1 Use of vap-1 inhibitors for treating fibrotic conditions

1 ... 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 ... 7860